BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cohesion Technologies, Inc. (CSON) Consolidation Update


10/19/2005 5:12:18 PM

VANCOUVER, Nov. 26 /PRNewswire-FirstCall/ -- Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), today provided an update on the consolidation of Cohesion Technologies announced previously during the Company's third quarter conference call.

In June of 2004 Angiotech purchased NeuColl, giving it two California subsidiaries in close proximity and on November 4, 2004, Angiotech announced its intention to make changes in the Company's California operations. As disclosed previously, Research and Development activities will be completely transferred to the Company's Vancouver headquarters by the end of December 2004. As a result, Dr. George Daniloff, General Manager of Cohesion and Senior Vice President of Research and Development will be concluding his employment as of the end of November 2004.

Efforts are underway to transfer VitaGEL manufacturing activities to Orthovita who will also distribute the product. Commercial launch of VitaGEL in the United States will commence in the first quarter of 2005. Once manufacturing has been transferred, the remaining positions at Cohesion will be eliminated.

Vancouver-based Angiotech Pharmaceuticals, Inc., a specialty pharmaceutical company focusing on drug-eluting medical devices and biomaterials, is dedicated to enhancing the performance of medical devices and biomaterials through the innovative uses of pharmacotherapeutics. To find out more about Angiotech Pharmaceuticals, Inc. , visit our website at http://www.angiotech.com/.

Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates," "believes," "may," "continue," "estimate," "expects," and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with the United States Securities and Exchange Commission or the Canadian securities regulators. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements.

CONTACTS: Todd Young, Angiotech Pharmaceuticals (Analysts & Investors) (604) 221-7676 ext 6933 Rui Avelar, Angiotech Pharmaceuticals, Inc. (Analysts) (604) 221-7676 ext 6996 Eric Starkman, Starkman & Associates (Media) (212) 252-8545 ext 12

Angiotech Pharmaceuticals, Inc.

CONTACT: Todd Young, Angiotech Pharmaceuticals (Analysts & Investors),(604) 221-7676 ext 6933; Rui Avelar, Angiotech Pharmaceuticals, Inc.(Analysts), (604) 221-7676 ext 6996; Eric Starkman, Starkman & Associates(Media), (212) 252-8545 ext 12



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES